🔗 Share this article

As the United States undertakes unprecedented adjustments to its vaccine schedules, an unexpected name appears unexpectedly: Dr. Tracy Beth Høeg, a Danish American physician and public health researcher who initially gained attention by expressing skepticism about COVID-19 vaccines in the global health crisis and has concentrated on possible deaths after COVID-19 immunization in her short position at the US Food and Drug Administration (FDA).

Proposed Overhauls to Childhood Vaccine Schedule

Public health authorities planned to reveal radical changes to the pediatric vaccine schedule recently, synchronizing the US with the Danish immunization schedule, it is understood – a substantial departure that would put the US out of alignment with many the global community with no evidence for improved outcomes. The announcement has been pushed back until the new year.

Instead of the top vaccines chief, Dr. Høeg is scheduled to address the audience at the gathering. She was newly appointed acting director of the FDA’s CDER, the fifth appointee to lead the division this year.

A Shift at the Regulatory Body

The acting appointment may indicate a closer partnership between the drug and biologics centers as Høeg and Prasad consolidate power at the regulatory agency – and it signals a renewed priority upon rolling back long-standing vaccines at the FDA.

Høeg has repeatedly called for halting certain pediatric immunization guidelines in the US so as to align more like Denmark's approach, a nation with universal health coverage and a citizenry about the size of Wisconsin’s.

To date public appearances, she has kept her attention on vaccines – traditionally the responsibility of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Questions Over Qualifications

Dr. Høeg has little discernible experience in medication creation, regulation or administrative roles, which has been customary for former heads of the biologics center. She has been employed at the FDA as a senior adviser to the FDA chief and the vaccine center since spring.

“It seems she lacks to have any of the qualifications” for leading the CDER, stated Jonathan Howard. “She’s never run a clinical trial. She has no expertise in running a large organization. She has no expertise in pharmaceutical oversight.”

Former heads of the center would “be deeply familiar with regulatory frameworks and the underlying principles of pharmaceutical innovation”, noted Janet Woodcock. “Objectively, she doesn’t have the sort of resume that previous people who ran CBER have had.”

This division has an enormous portfolio at the agency, the former commissioner pointed out.

“Everybody just focuses on the new drug program, but the generic drug division authorizes a multitude of off-brand pharmaceuticals. There is also a biologic copycat branch, OTC medication office and more, and each of these must be supervised,” Woodcock said. “The thing you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

Additionally, a substantial administrative element to the position, which oversees over 5,000 personnel. “It’s a massive leadership role, if you do it right,” the former official concluded.

Response and Contentious Initiatives

Regarding inquiries about Dr. Høeg's fitness for the role and whether this assignment signifies more teamwork among agency officials on vaccines, a spokesperson responded that the “inquiries stem from inaccurate presumptions”.

“Her resume matches the responsibilities of her job,” the representative said, noting the time Dr. Høeg spent guiding the agency head on “drug safety and oversight research, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg takes over the agency head's recently launched fast-track approval initiative, a contentious one-day drug-approval program that allegedly concerned her predecessors. “How are these medications being selected for this fast-track system? Who is making the choices?” Dr. Howard questioned. “There is a lot of secrecy occurring at the agency right now.”

Broadly speaking, he stated, “the Food and Drug Administration seems to be moving towards more relaxed oversight of pharmaceuticals, except for vaccines.”

Documented Past Work on Immunizations

Regarding vaccines, Høeg has a more established, if problematic, past, some experts have noted. She released a analysis using unconfirmed crowd-sourced reports to determine the incidence of myocarditis after COVID-19 vaccination. She counseled the Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to suggest COVID-19 vaccinations are more dangerous than they are.

Among her “wish list” for the incoming government featured revising guidelines for new vaccines and discontinuing “unnecessary” immunizations, she stated after the election on a audio program. At the FDA, Høeg has according to sources proposed barring adolescent males from receiving COVID-19 vaccinations.

“She’s an complete dogmatist who begins with her preconceived notions and tailors the evidence to accommodate the evidence in a very disingenuous, fraudulent manner,” Dr. Howard said.

Taking Control and a “Push for Payback”

Høeg became part of other dissenters, {like|